// App-Quantinova.ai

TPS3151 : SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).

Researchers

Presenter

  • Tom Stinchcombe

Principal Investigators

  • Bradley J. Monk

  • Alicia Frances Clare Okines

  • Paula R Pohlmann

  • Evan Y. Yu

  • Tanios S. Bekaii-Saab

  • Yoshiaki Nakamura

  • David M. O'Malley

  • Vicky Kang

  • Luke N. Walker

  • Martin Reck

Medical Centers

  • Duke Cancer Institute, Durham, NC, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ, The Royal Marsden NHS Foundation Trust, London, United Kingdom

  • Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • The Ohio State University, The James Comprehensive Cancer Center, Columbus, OH, Seagen Inc., Bothell, WA, LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany

Locations

  • United Kingdom

  • Japan

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Cervical cancer

  • Solid malignancies

  • Non Small Cell Lung cancer

  • Transplant renal artery stenosis

Biomarkers

  • Cyclin-dependent kinase 4

  • Circulating DNA

Drug/Treatment

  • Bevacizumab

  • Fulvestrant

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • NCT04579380

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved